1.A Case of Coronary Artery Bypass Grafting for Left Coronary Ostial Stenosis Following Aortic Valve Replacement.
Makoto Kamada ; Ryosei Kuribayasi ; Satosi Sekine ; Hiroaki Aida ; Keiji Seki ; Atusi Meguro ; Keitaro Iijima ; Tadaaki Abe
Japanese Journal of Cardiovascular Surgery 1994;23(1):42-45
A rare case of left coronary ostial stenosis following aortic valve replacement (AVR) was reported. A 67-year-old man had undergone AVR for aortic stenosis and regurgitation. During the procedure basket tip cannula was utilized for selective coronary perfusion. He began to complain of chest pain 4 months after surgery, and coronary arteriography revealed a 99% stenosis at the left coronary ostium. Emergency coronary artery bypass grafting (CABG) to the LAD using a saphenous vein graft was successfully performed. The angina pectoris developing after AVR suggests that coronary ostial injury was caused by selective coronary perfusion cannula. The disease progresses rapidly in the absence of sufficient collaterals, and emergency CABG is needed to prevent critical myocardial infarction and sudden death.
2.Mycotic Abdominal Aortic Aneurysm: A Case Report of Successful Anatomic Reconstruction.
Makoto Kamada ; Tadaaki Abe ; Ryousei Kuribayashi ; Satoshi Sekine ; Hiroaki Aida ; Keiji Seki ; Atsushi Meguro ; Yoshiki Shibata ; Keitarou Iijima ; Katsuyuki Kondoh
Japanese Journal of Cardiovascular Surgery 1995;24(1):53-55
A 63-year-old woman who was diagnosed a having impending rupture of abdominal aortic aneurysm underwent urgent anatomic reconstruction. Histopathological findings revealed abscess formation around the aneurysmal wall, and a definitive diagnosis of mycotic aneurysm was established. Successful management of this rare aortic disease depends on early accurate diagnosis, control of infection and careful surgical management.
3.Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries.
Taku KOBAYASHI ; Tadakazu HISAMATSU ; Yasuo SUZUKI ; Haruhiko OGATA ; Akira ANDOH ; Toshimitsu ARAKI ; Ryota HOKARI ; Hideki IIJIMA ; Hiroki IKEUCHI ; Yoh ISHIGURO ; Shingo KATO ; Reiko KUNISAKI ; Takayuki MATSUMOTO ; Satoshi MOTOYA ; Masakazu NAGAHORI ; Shiro NAKAMURA ; Hiroshi NAKASE ; Tomoyuki TSUJIKAWA ; Makoto SASAKI ; Kaoru YOKOYAMA ; Naoki YOSHIMURA ; Kenji WATANABE ; Miiko KATAFUCHI ; Mamoru WATANABE ; Toshifumi HIBI
Intestinal Research 2018;16(2):168-177
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.
Asian Continental Ancestry Group
;
Colectomy
;
Colitis, Ulcerative
;
Colorectal Neoplasms
;
Consensus
;
Crohn Disease
;
Disease Management*
;
Disease Progression
;
Early Intervention (Education)
;
Epidemiology
;
Expert Testimony
;
Gastrointestinal Tract
;
Hospitalization
;
Humans
;
Inflammatory Bowel Diseases*
;
Japan*
;
Prevalence
;
Prognosis
4.A case of autoimmune enteropathy with CTLA4 haploinsufficiency
Haruka MIYAZAKI ; Namiko HOSHI ; Michitaka KOHASHI ; Eri TOKUNAGA ; Yuna KU ; Haruka TAKENAKA ; Makoto OOI ; Nobuyuki YAMAMOTO ; Suguru UEMURA ; Noriyuki NISHIMURA ; Kazumoto IIJIMA ; Keisuke JIMBO ; Tsubasa OKANO ; Akihiro HOSHINO ; Kohsuke IMAI ; Hirokazu KANEGANE ; Ichiro KOBAYASHI ; Yuzo KODAMA
Intestinal Research 2022;20(1):144-149
Autoimmune enteropathy (AIE) is a rare disease, characterized by intractable diarrhea, villous atrophy of the small intestine, and the presence of circulating anti-enterocyte autoantibodies. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, and mutations in FOXP3, which is a master gene of regulatory T cells (Tregs), are major causes of AIE. Recent studies have demonstrated that mutations in other Treg-associated genes, such as CD25 and CTLA4, show an IPEX-like phenotype. We present the case of a 13-year-old girl with CTLA4 haploinsufficiency, suffering from recurrent immune thrombocytopenic purpura and intractable diarrhea. We detected an autoantibody to the AIE-related 75 kDa antigen (AIE-75), a hallmark of the IPEX syndrome, in her serum. She responded well to a medium dose of prednisolone and a controlled dose of 6-mercaptopurine (6-MP), even after the cessation of prednisolone administration. Serum levels of the soluble interleukin-2 receptor and immunoglobulin G (IgG) were useful in monitoring disease activity during 6-MP therapy. In conclusion, autoimmune-mediated mechanisms, similar to the IPEX syndrome, may be involved in the development of enteropathy in CTLA4 haploinsufficiency. Treatment with 6-MP and monitoring of disease activity using serum levels of soluble interleukin-2 receptor and IgG is suggested for such cases.
5.Efficacy and safety of glecaprevir and pibrentasvir combination therapy in old-aged patients with chronic hepatitis C virus infection
Shunji WATANABE ; Naoki MORIMOTO ; Kouichi MIURA ; Toshimitsu MUROHISA ; Toshiyuki TAHARA ; Takashi SATO ; Shigeo TANO ; Yukimura FUKAYA ; Hidekazu KURATA ; Yukishige OKAMURA ; Norikatsu NUMAO ; Keita UEHARA ; Kozue MURAYAMA ; Katsuyuki NAKAZAWA ; Hitoshi SUGAYA ; Hiroaki YOSHIZUMI ; Makoto IIJIMA ; Mamiko TSUKUI ; Takuya HIROSAWA ; Yoshinari TAKAOKA ; Hiroaki NOMOTO ; Hiroshi MAEDA ; Rie GOKA ; Norio ISODA ; Hironori YAMAMOTO
Journal of Rural Medicine 2020;15(4):139-145
Objective: Combination therapy with glecaprevir and pibrentasvir (G/P) has been shown to provide a sustained virologic response (SVR) rate of >97% in patients with chronic hepatitis C virus (HCV) infection in the first published real-world Japanese data. However, a recently published study showed that the treatment was often discontinued in patients ≥75 years old, resulting in low SVR in intention-to-treat (ITT) analysis. Thus, our aim was to evaluate real-world data for G/P therapy in patients ≥75 years of age, the population density of which is high in “rural” regions.Patients and Methods: We conducted a multicenter study to assess the efficacy and safety of G/P therapy for chronic HCV infection, in the North Kanto area in Japan.Results: Of the 308 patients enrolled, 294 (95.5%) completed the treatment according to the protocol. In ITT and per-protocol analyses, the overall SVR12 rate was 97.1% and 99.7%, respectively. The old-aged patients group consisted of 59 participants, 56 of whom (94.9%) completed the scheduled protocol. Although old-aged patients tended to have non-SVR factors such as liver cirrhosis, history of HCC, and prior DAA therapies, the SVR12 rates in old-aged patients were 98.3% and 100% in the ITT and PP analyses, respectively. Of 308 patients enrolled, adverse events were observed in 74 patients (24.0%), with grade ≥3 events in 8 patients (2.6%). There was no significant difference in any grade and grade ≥3 adverse events between the old-aged group and the rest of the study participants. Only one patient discontinued the treatment because of adverse events.Conclusion: G/P therapy is effective and safe for old-aged patients.